Psychiatry & Neurology Doctors in Zuni, NM Accepting Medicare

1 Psychiatry & Neurology doctors found. Showing 1 - 1

Dr. Joy Della Mcquery Vala, MD Psychiatry & Neurology - Psychiatry Medicare: Medicare Enrolled Practice Location: Route 301 North B Street, Zuni, NM 87327 Phone: 505-782-4431

News Archive

Study identifies SARS-CoV-2 spike conformation exposing potential new therapeutic targets

Researchers in the United States have demonstrated that the viral spike protein used by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to infect host cells adopts an open conformation exposing novel epitopes that could serve as targets for therapeutic strategies to protect against coronavirus disease 2019 (COVID-19).

TZDs might serve as new agents for addiction treatment

Thiazolidinediones are a class of medications that are commonly prescribed to treat type-2 diabetes, while fibrates are a structurally-related class of medications that are prescribed to modulate lipid levels in both diabetic and non-diabetic patients to help reduce the risk of cardiovascular disease.

GOP lawmaker set to release health care 'declaration'

Republicans are seeking consensus on health care now that Democrats can no longer go it alone, having lost their filibuster-proof 60-vote Senate majority, NPR reports. Senior Republicans are "shopping around" policy ideas they say everyone could agree with "off the bat," including a cap on certain malpractice damages and allowing insurers to sell plans across state lines. But, some observers note that even when they were in the majority, Republicans failed to agree even on those issues (Rovner, 1/26).

Groundbreaking CURATE.AI platform halts progression of advanced cancer

A translational research team led by the National University of Singapore has harnessed CURATE.AI, a powerful artificial intelligence platform, to successfully treat a patient with advanced cancer, completely halting disease progression.

Sorrento Therapeutics acquires Concortis Biosystems

Sorrento Therapeutics, Inc. announced today that it has completed its acquisition of Concortis Biosystems, Corp., providing Sorrento with a comprehensive technology platform to create a new generation of homogenous antibody drug conjugates with site-specific toxin conjugation and consistent drug-antibody ratios. With the close of the deal, Sorrento has issued an aggregate of 1,331,978 shares of its common stock to the Concortis shareholders. Based on the closing share price on December 18, 2013, the transaction is valued at $11.3 million.

Read more Medical News

› Verified 8 days ago